JP2004537500A - 腫瘍の増殖の阻害および免疫応答の増強のための方法および組成物 - Google Patents
腫瘍の増殖の阻害および免疫応答の増強のための方法および組成物 Download PDFInfo
- Publication number
- JP2004537500A JP2004537500A JP2002555834A JP2002555834A JP2004537500A JP 2004537500 A JP2004537500 A JP 2004537500A JP 2002555834 A JP2002555834 A JP 2002555834A JP 2002555834 A JP2002555834 A JP 2002555834A JP 2004537500 A JP2004537500 A JP 2004537500A
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- subject
- virus
- tumor
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 120
- 230000004614 tumor growth Effects 0.000 title claims abstract description 23
- 239000000203 mixture Substances 0.000 title claims abstract description 16
- 230000028993 immune response Effects 0.000 title claims abstract description 13
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 7
- 230000002401 inhibitory effect Effects 0.000 title claims description 15
- 239000003112 inhibitor Substances 0.000 claims abstract description 123
- 108090000176 Interleukin-13 Proteins 0.000 claims abstract description 121
- 102000003816 Interleukin-13 Human genes 0.000 claims abstract description 120
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 83
- 229960005486 vaccine Drugs 0.000 claims abstract description 23
- 230000004044 response Effects 0.000 claims abstract description 9
- 210000004027 cell Anatomy 0.000 claims description 62
- 102100024219 T-cell surface glycoprotein CD1a Human genes 0.000 claims description 29
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 26
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 25
- 241000700605 Viruses Species 0.000 claims description 23
- 230000000694 effects Effects 0.000 claims description 21
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 17
- 229920001184 polypeptide Polymers 0.000 claims description 16
- 239000003446 ligand Substances 0.000 claims description 15
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 13
- 241000282414 Homo sapiens Species 0.000 claims description 12
- 108010074328 Interferon-gamma Proteins 0.000 claims description 12
- 102000004559 Interleukin-13 Receptors Human genes 0.000 claims description 10
- 108010017511 Interleukin-13 Receptors Proteins 0.000 claims description 10
- 241000701806 Human papillomavirus Species 0.000 claims description 9
- 230000012010 growth Effects 0.000 claims description 9
- 241000701022 Cytomegalovirus Species 0.000 claims description 8
- 241000711549 Hepacivirus C Species 0.000 claims description 8
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000011859 microparticle Substances 0.000 claims description 6
- 244000052769 pathogen Species 0.000 claims description 6
- 230000001717 pathogenic effect Effects 0.000 claims description 6
- 108700028369 Alleles Proteins 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 150000007523 nucleic acids Chemical class 0.000 claims description 5
- 241000700721 Hepatitis B virus Species 0.000 claims description 4
- 241000598436 Human T-cell lymphotropic virus Species 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- 229940123155 T cell inhibitor Drugs 0.000 claims description 4
- 239000005557 antagonist Substances 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 4
- 108020001507 fusion proteins Proteins 0.000 claims description 4
- 102000037865 fusion proteins Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- 108060003951 Immunoglobulin Proteins 0.000 claims description 3
- 102000008070 Interferon-gamma Human genes 0.000 claims description 3
- 208000037581 Persistent Infection Diseases 0.000 claims description 3
- 108700025716 Tumor Suppressor Genes Proteins 0.000 claims description 3
- 102000044209 Tumor Suppressor Genes Human genes 0.000 claims description 3
- 230000000692 anti-sense effect Effects 0.000 claims description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 3
- 230000003111 delayed effect Effects 0.000 claims description 3
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 3
- 102000018358 immunoglobulin Human genes 0.000 claims description 3
- 229960003130 interferon gamma Drugs 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 108700025699 DCC Genes Proteins 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 108700025701 Retinoblastoma Genes Proteins 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 210000000601 blood cell Anatomy 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 108700025694 p53 Genes Proteins 0.000 claims description 2
- 230000000069 prophylactic effect Effects 0.000 claims description 2
- 230000000306 recurrent effect Effects 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 3
- 208000000389 T-cell leukemia Diseases 0.000 claims 3
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims 3
- 238000002271 resection Methods 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 241001529936 Murinae Species 0.000 claims 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 231100000065 noncytotoxic Toxicity 0.000 claims 1
- 230000002020 noncytotoxic effect Effects 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000003073 testicular leukemia Diseases 0.000 claims 1
- 201000002814 testicular lymphoma Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 abstract description 4
- 230000003915 cell function Effects 0.000 abstract description 4
- 230000009401 metastasis Effects 0.000 abstract description 4
- 241000699670 Mus sp. Species 0.000 description 124
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 57
- 210000001744 T-lymphocyte Anatomy 0.000 description 54
- 102000004388 Interleukin-4 Human genes 0.000 description 39
- 108090000978 Interleukin-4 Proteins 0.000 description 39
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 24
- 239000007924 injection Substances 0.000 description 19
- 238000002347 injection Methods 0.000 description 19
- 210000000581 natural killer T-cell Anatomy 0.000 description 14
- 102000004127 Cytokines Human genes 0.000 description 12
- 108090000695 Cytokines Proteins 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 108040006852 interleukin-4 receptor activity proteins Proteins 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 239000008194 pharmaceutical composition Substances 0.000 description 11
- 102100037850 Interferon gamma Human genes 0.000 description 9
- 239000011324 bead Substances 0.000 description 9
- 230000000638 stimulation Effects 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 230000018711 interleukin-13 production Effects 0.000 description 8
- 210000004988 splenocyte Anatomy 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 230000001900 immune effect Effects 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 230000003828 downregulation Effects 0.000 description 6
- 238000001325 log-rank test Methods 0.000 description 6
- 230000005748 tumor development Effects 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 102000013968 STAT6 Transcription Factor Human genes 0.000 description 5
- 108010011005 STAT6 Transcription Factor Proteins 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 230000004913 activation Effects 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 230000037451 immune surveillance Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000017307 interleukin-4 production Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 229940023041 peptide vaccine Drugs 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- 108010054623 HIV-1 gp160 (315-329) Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000016396 cytokine production Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229940033330 HIV vaccine Drugs 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 2
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 108700020978 Proto-Oncogene Proteins 0.000 description 2
- 102000052575 Proto-Oncogene Human genes 0.000 description 2
- 239000008156 Ringer's lactate solution Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000010805 cDNA synthesis kit Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000002642 intravenous therapy Methods 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 108700024542 myc Genes Proteins 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 108700042226 ras Genes Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 108700001666 APC Genes Proteins 0.000 description 1
- 108010066676 Abrin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 108010041397 CD4 Antigens Proteins 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 241000218645 Cedrus Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 102100022297 Integrin alpha-X Human genes 0.000 description 1
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 description 1
- 102000010787 Interleukin-4 Receptors Human genes 0.000 description 1
- 108010038486 Interleukin-4 Receptors Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 101150039798 MYC gene Proteins 0.000 description 1
- 101001003131 Mus musculus Interleukin-13 receptor subunit alpha-2 Proteins 0.000 description 1
- 101001043827 Mus musculus Interleukin-2 Proteins 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 1
- 101150040459 RAS gene Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- BMLSTPRTEKLIPM-UHFFFAOYSA-I calcium;potassium;disodium;hydrogen carbonate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].OC([O-])=O BMLSTPRTEKLIPM-UHFFFAOYSA-I 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008355 dextrose injection Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000011502 immune monitoring Methods 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 108040003607 interleukin-13 receptor activity proteins Proteins 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000003651 pro-proliferative effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 208000011581 secondary neoplasm Diseases 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 231100000606 suspected carcinogen Toxicity 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55538—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69360000A | 2000-10-20 | 2000-10-20 | |
| US31818501P | 2001-09-07 | 2001-09-07 | |
| PCT/US2001/051339 WO2002055100A2 (en) | 2000-10-20 | 2001-10-22 | Method and composition for inhibition of tumor growth and enhancing an immune response |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008262301A Division JP2009046512A (ja) | 2000-10-20 | 2008-10-08 | 腫瘍の増殖の阻害および免疫応答の増強のための方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004537500A true JP2004537500A (ja) | 2004-12-16 |
| JP2004537500A5 JP2004537500A5 (cg-RX-API-DMAC7.html) | 2005-04-21 |
Family
ID=26981351
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002555834A Pending JP2004537500A (ja) | 2000-10-20 | 2001-10-22 | 腫瘍の増殖の阻害および免疫応答の増強のための方法および組成物 |
| JP2008262301A Pending JP2009046512A (ja) | 2000-10-20 | 2008-10-08 | 腫瘍の増殖の阻害および免疫応答の増強のための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008262301A Pending JP2009046512A (ja) | 2000-10-20 | 2008-10-08 | 腫瘍の増殖の阻害および免疫応答の増強のための方法および組成物 |
Country Status (8)
| Country | Link |
|---|---|
| EP (2) | EP1333850B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2004537500A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE405282T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2002243443A1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE60135481D1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK1333850T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2311558T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2002055100A2 (cg-RX-API-DMAC7.html) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008528643A (ja) * | 2005-02-04 | 2008-07-31 | スルバック アーぺーエス | サバイビンペプチドワクチン |
| JP2017014254A (ja) * | 2014-02-21 | 2017-01-19 | Ｉｄａｃセラノスティクス株式会社 | 固形がんの治療剤 |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050069546A1 (en) * | 2003-09-30 | 2005-03-31 | Yaron Ilan | Educated NKT cells and their uses in the treatment of immune-related disorders |
| DK2805728T3 (da) * | 2003-12-23 | 2020-04-20 | Genentech Inc | Hidtil ukendte anti-IL13-antistoffer og anvendelser deraf |
| WO2005091853A2 (en) * | 2004-02-27 | 2005-10-06 | Centocor, Inc. | Methods and compositions for treating il-13 related pathologies |
| AR049390A1 (es) | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| US7501121B2 (en) | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
| AU2005307831A1 (en) | 2004-11-17 | 2006-05-26 | Amgen, Inc. | Fully human monoclonal antibodies to IL-13 |
| MY161894A (en) | 2006-09-08 | 2017-05-15 | Abbvie Bahamas Ltd | Interleukin-13 binding proteins |
| AU2010269120B2 (en) * | 2009-07-06 | 2015-09-24 | The Australian National University | Immunomodulating compositions comprising interleukin 13 inhibitors and uses therefor |
| TWI666447B (zh) | 2010-12-16 | 2019-07-21 | 建南德克公司 | 關於ｔｈ２抑制作用之診斷及治療 |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| GB2506086A (en) | 2011-10-21 | 2014-03-19 | Abbvie Inc | Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon |
| CN104023726A (zh) | 2011-10-21 | 2014-09-03 | 艾伯维公司 | 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333) |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| EP3044323B1 (en) | 2013-09-13 | 2022-04-06 | F. Hoffmann-La Roche AG | Methods for detecting and quantifying host cell protein in cell lines |
| JP6751344B2 (ja) | 2013-09-13 | 2020-09-02 | ジェネンテック， インコーポレイテッド | 精製された組み換えポリペプチドを含む方法及び組成物 |
| US11192914B2 (en) | 2016-04-28 | 2021-12-07 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| TW202509218A (zh) * | 2023-07-12 | 2025-03-01 | 亨利傑克森軍方醫學基金會 | 用於抑制自然殺手細胞之組合物及方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6294322B1 (en) | 1988-01-26 | 2001-09-25 | The United States Of America As Represented By The Department Of Health And Human Services | Multideterminant peptides that elicit helper T-lymphocyte cytotoxic T-lymphocyte and neutralizing antibody responses against HIV-1 |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| WO1994004680A1 (en) * | 1992-08-21 | 1994-03-03 | Schering Corporation | Human interleukin-13 |
| US20010053371A1 (en) * | 1999-01-07 | 2001-12-20 | Waldemar Debinski | Method for diagnosing, imaging, and treating tumors using restrictive receptor for interleukin 13 |
| JPH09150569A (ja) | 1995-11-29 | 1997-06-10 | Riso Kagaku Corp | 色画像形成用シート |
| GB9625899D0 (en) * | 1996-12-13 | 1997-01-29 | Glaxo Group Ltd | Substances and their uses |
| US6013258A (en) | 1997-10-09 | 2000-01-11 | Zycos Inc. | Immunogenic peptides from the HPV E7 protein |
| NZ512942A (en) * | 1998-12-14 | 2004-01-30 | Univ Johns Hopkins | Polynucleotides encoding the IL-13 binding chains of the interleukin receptor, pharmaceutical compositions comprising the protein and methods of identifying inhibitors |
| ATE286026T1 (de) * | 1999-02-10 | 2005-01-15 | Mitsubishi Pharma Corp | Amid-derivate und deren medizinische verwendung |
| EP1268794A2 (en) * | 2000-04-07 | 2003-01-02 | Heska Corporation | Compositions and methods related to canine igg and canine il-13 receptors |
-
2001
- 2001-10-22 DK DK01989341T patent/DK1333850T3/da active
- 2001-10-22 ES ES01989341T patent/ES2311558T3/es not_active Expired - Lifetime
- 2001-10-22 JP JP2002555834A patent/JP2004537500A/ja active Pending
- 2001-10-22 WO PCT/US2001/051339 patent/WO2002055100A2/en not_active Ceased
- 2001-10-22 AT AT01989341T patent/ATE405282T1/de not_active IP Right Cessation
- 2001-10-22 DE DE60135481T patent/DE60135481D1/de not_active Expired - Lifetime
- 2001-10-22 EP EP01989341A patent/EP1333850B1/en not_active Revoked
- 2001-10-22 AU AU2002243443A patent/AU2002243443A1/en not_active Abandoned
- 2001-10-22 EP EP08105062A patent/EP2027867A1/en not_active Withdrawn
-
2008
- 2008-10-08 JP JP2008262301A patent/JP2009046512A/ja active Pending
Non-Patent Citations (6)
| Title |
|---|
| JPN6008016323, ＲＵＴＨ， Ｊ．Ｈ．， ｅｔ ａｌ．, "ＩＮＴＥＲＬＥＵＫＩＮ ４ ＡＮＤ １３ ＰＡＲＴＩＣＩＰＡＴＩＯＮ ＩＮ ＭＹＣＯＢＡＣＴＥＲＩＡＬ （ｔｙｐｅ−１） ＡＮＤ ＳＣＨＩＳＴＯＳＯＭＡＬ （ｔｙｐｅ−２） ＡＮＴＩＧＥＮ−ＥＬＩＣＩ", ＣＹＴＯＫＩＮＥ, 200005, Ｖｏｌ．１２， Ｎｏ．５, ｐ．４３２−４４４ * |
| JPN6008016324, ＳＥＲＶＥ， Ｈ．， ｅｔ ａｌ．, "Ｉｎｈｉｂｉｔｉｏｎ ｏｆ Ｐｒｏｌｉｆｅｒａｔｉｏｎ ａｎｄ Ｃｌｏｎａｌ Ｇｒｏｗｔｈ ｏｆ Ｈｕｍａｎ Ｂｒｅｓｔ Ｃａｎｃｅｒ Ｃｅｌｌｓ ｂｙ Ｉｎｔｅｒｌｅｕｋｉｎ １３", ＣＡＮＣＥＲ ＲＥＳＥＡＲＣＨ, 19960801, Ｖｏｌ．５６， Ｎｏ．１５, ｐ．３５８３−３５８８ * |
| JPN6008016325, ＢＡＩＬＥＲ， Ｒ．Ｔ．， ｅｔ ａｌ．, "ＩＬ−１３ ａｎｄ ＴＮＦ−α ｉｎｈｉｂｉｔ ｄｕａｌ−ｔｒｏｐｉｃ ＨＩＶ−１ ｉｎ ｐｒｉｍａｒｙ ｍａｃｒｏｐｈａｇｅｓ ｂｙ ｒｅｄｕｃｔｉｏｎ ｏｆ ｓｕｒｆａｃｅ ｅｘｐｒｅｓｓｉｏｎ", ＥＵＲＯＰＥＡＮ ＪＯＵＲＮＡＬ ＯＦ ＩＭＭＵＮＯＬＯＧＹ, 200005, Ｖｏｌ．３０， Ｎｏ．５, ｐ．１３４０−１３４９ * |
| JPN6008016326, ＣＨＩＡＲＡＭＯＮＴＥ， Ｍ．Ｇ．， ｅｔ ａｌ．, "Ａｎ ＩＬ−１３ ｉｎｈｉｂｉｔｏｒ ｂｌｏｃｋｓ ｔｈｅ ｄｅｖｅｌｏｐｍｅｎｔ ｏｆ ｈｅｐａｔｉｃ ｆｉｂｒｏｓｉｓ ｄｕｒｉｎｇ ａ Ｔ−ｈｅｌｐｅｒ ｔｙｐｅ ２−ｄｏｍｉｎａｔｅｄ ｉｎｆ", Ｔｈｅ Ｊｏｕｒｎａｌ ｏｆ Ｃｌｉｎｉｃａｌ Ｉｎｖｅｓｔｉｇａｔｉｏｎ, 199909, Ｖｏｌ．４０１， Ｎｏ．６, ｐ．７７７−７８５ * |
| JPN6008016327, ＬＯＰＥＺ， Ｍ．， ｅｔ ａｌ．, "ＩＬ−１３ ｉｎｄｕｃｅｓ ＣＤ３４＋ ｃｅｌｌｓ ｉｓｏｌａｔｅｄ ｆｒｏｍ Ｇ−ＣＳＦ ｍｏｂｉｌｉｚｅｄ ｂｌｏｏｄ ｔｏ ｄｉｆｆｅｒｅｎｔｉａｔｅ ｉｎ ｖｉｔｒｏ ｉｎｔｏ ｐｏｔｅｎｔ", Ｊｏｕｒｎａｌ ｏｆ Ｉｍｍｕｎｏｌｏｇｉｃａｌ Ｍｅｔｈｏｄｓ, 19971027, Ｖｏｌ．２０８， Ｎｏ．２, ｐ．１１７−１２９ * |
| JPN7008003165, ＬＥＢＥＬ−ＢＩＮＡＹ， Ｓ．， ｅｔ ａｌ．, "Ｅｘｐｅｒｉｍｅｎｔａｌ ｇｅｎｅ ｔｈｅｒａｐｙ ｏｆ ｃａｎｃｅｒ ｕｓｉｎｇ ｔｕｍｏｒ ｃｅｌｌｓ ｅｎｇｅｎｅｅｒｅｄ ｔｏ ｓｅｃｒｅｔｅ ｉｎｔｅｒｌｅｕｋｉｎ−１３", ＥＵＲＯＰＥＡＮ ＪＯＵＲＮＡＬ ＯＦ ＩＭＭＵＮＯＬＯＧＹ, 199508, Ｖｏｌ．２５， Ｎｏ．８, ｐ．２３４０−２３４８ * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008528643A (ja) * | 2005-02-04 | 2008-07-31 | スルバック アーぺーエス | サバイビンペプチドワクチン |
| JP2017014254A (ja) * | 2014-02-21 | 2017-01-19 | Ｉｄａｃセラノスティクス株式会社 | 固形がんの治療剤 |
| JPWO2015125652A1 (ja) * | 2014-02-21 | 2017-03-30 | Ｉｄａｃセラノスティクス株式会社 | 固形がんの治療剤 |
| JP2019070056A (ja) * | 2014-02-21 | 2019-05-09 | Ｉｄａｃセラノスティクス株式会社 | 固形がんの治療剤 |
| JP7041439B2 (ja) | 2014-02-21 | 2022-03-24 | Ｉｄａｃセラノスティクス株式会社 | 固形がんの治療剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002055100A2 (en) | 2002-07-18 |
| ES2311558T3 (es) | 2009-02-16 |
| JP2009046512A (ja) | 2009-03-05 |
| DK1333850T3 (da) | 2008-12-01 |
| DE60135481D1 (de) | 2008-10-02 |
| AU2002243443A1 (en) | 2002-07-24 |
| WO2002055100A3 (en) | 2003-03-27 |
| EP1333850B1 (en) | 2008-08-20 |
| EP2027867A1 (en) | 2009-02-25 |
| ATE405282T1 (de) | 2008-09-15 |
| AU2002243443A8 (en) | 2005-10-13 |
| EP1333850A2 (en) | 2003-08-13 |
| WO2002055100A9 (en) | 2006-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009046512A (ja) | 腫瘍の増殖の阻害および免疫応答の増強のための方法および組成物 | |
| US7504101B2 (en) | Methods for enhancing antigen-specific immune response using antibodies that bind OX-40 | |
| EP1060247B1 (en) | Compositions containing an ox-40 receptor binding agent or a nucleic acid encoding the same and methods for enhancing antigen-specific immune response | |
| Alexander-Miller et al. | Supraoptimal Peptide–Major Histocompatibility Complex Causes a Decrease in Bcl-2 Levels and Allows Tumor Necrosis Factor α Receptor II–mediated Apoptosis of Cytotoxic T Lymphocytes | |
| JP4787439B2 (ja) | 免疫調節因子であるｂａｆｆレセプター（ｂｃｍａ） | |
| Saha et al. | Combination of CTL‐associated Antigen‐4 blockade and depletion of CD25+ regulatory T cells enhance tumour immunity of dendritic cell‐based vaccine in a mouse model of colon cancer | |
| US20230078665A1 (en) | Cell compositions and methods for cancer therapy | |
| US20030039653A1 (en) | Methods of enhancing T cell responsiveness | |
| TWI222453B (en) | Ligand for herpes simplex virus entry mediator and methods of use | |
| KR20060130731A (ko) | Ｔｉｍ-1, ｔｉｍ-2 및 ｔｉｍ-4 기능을 조절하여 면역반응을 조절하는 방법 | |
| Takayama et al. | Antigen-specific directional target cell lysis by perforin-negative T lymphocyte clones | |
| USRE39789E1 (en) | Tumor therapy | |
| AU2002302070B2 (en) | Compositions containing an OX-40 receptor binding agent or a nucleic acid encoding the same and methods for enhancing antigen-specific immune response | |
| MXPA00008176A (en) | Compositions containing an ox-40 receptor binding agent or a nucleic acid encoding the same and methods for enhancing antigen-specific immune response | |
| HK1126246A (en) | Compositions containing an ox-40 receptor binding agent or a nucleic acid encoding the same and methods for enhancing antigen-specific immune response | |
| Sutherland | BAFF regulation of peripheral T cell responses | |
| Rivoltini et al. | Tumor immunology: Clinical perspectives | |
| NZ788539A (en) | Anti-gitr antibodies and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041012 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080408 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080626 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080703 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080805 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080812 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080903 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080910 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081008 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20081008 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091202 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100216 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100223 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100531 |